Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Cancer Other Than Leukemia”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Testing effectiveness (Phase 2)Study completedNCT01428128
What this trial is testing

Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector

Who this might be right for
Cancer Other Than Leukemia
The University of Texas Health Science Center at San Antonio 50
Testing effectiveness (Phase 2)Study completedNCT01361334
What this trial is testing

Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible

Who this might be right for
Acute Myeloid Leukemia
University Hospital Muenster 20
Testing effectiveness (Phase 2)Study completedNCT01203722
What this trial is testing

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

Who this might be right for
Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 87
Early research (Phase 1)Study completedNCT01462175
What this trial is testing

A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia

Who this might be right for
Neoplasms
Hoffmann-La Roche 99
Early research (Phase 1)Study completedNCT00559533
What this trial is testing

RO5045337 [RG7112] in Patients With Advanced Solid Tumors

Who this might be right for
Neoplasms
Hoffmann-La Roche 106
Testing effectiveness (Phase 2)Ended earlyNCT01018069
What this trial is testing

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Who this might be right for
Leukemia
Aegera Therapeutics 60
Early research (Phase 1)Ended earlyNCT01066468
What this trial is testing

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Who this might be right for
Chronic Myeloid Leukemia (CML)Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)
Novartis Pharmaceuticals 3
Early research (Phase 1)Study completedNCT00585195
What this trial is testing

Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Who this might be right for
Non-Small Cell Lung Cancer ALK-positiveNon-Small Cell Lung Cancer c-Met DependentNon-Small Cell Lung Cancer ROS Marker Positive+2 more
Pfizer 596
Not applicableNot Yet RecruitingNCT06084923
What this trial is testing

Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression

Who this might be right for
Chronic Lymphocytic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 73
Testing effectiveness (Phase 2)Ended earlyNCT01350258
What this trial is testing

Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps

Who this might be right for
Hematologic MalignanciesAcute LeukemiaMyelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes+4 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 8
Not applicableStudy completedNCT04938115
What this trial is testing

Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia

Who this might be right for
Leukemia, T Cell
Hebei Senlang Biotechnology Inc., Ltd. 50